Abstract | This year is the tenth anniversary of the publication in this journal of a model suggesting the existence of 'tumour progenitor genes'. These genes are epigenetically disrupted at the earliest stages of malignancies, even before mutations, and thus cause altered differentiation throughout tumour evolution. The past decade of discovery in cancer epigenetics has revealed a number of similarities between cancer genes and stem cell reprogramming genes, widespread mutations in epigenetic regulators, and the part played by chromatin structure in cellular plasticity in both development and cancer. In the light of these discoveries, we suggest here a framework for cancer epigenetics involving three types of genes: 'epigenetic mediators', corresponding to the tumour progenitor genes suggested earlier; 'epigenetic modifiers' of the mediators, which are frequently mutated in cancer; and 'epigenetic modulators' upstream of the modifiers, which are responsive to changes in the cellular environment and often linked to the nuclear architecture. We suggest that this classification is helpful in framing new diagnostic and therapeutic approaches to cancer.
Ten years ago, it was suggested that, in addition to onco genes and tumour suppressor genes, epigenetic altera tions disrupt the expression of hypothesized 'tumour progenitor genes' that mediate stemness at the earliest stage of carcinogenesis, even as a field effect in normal tissues 1 . Epigenetically altered tumour progenitor genes were proposed to increase the likelihood of cancer when genetic mutations occurred and these same genes were suggested to be involved throughout tumour progres sion, helping to explain properties such as invasion and metastasis 1 . In the 10 years since this model was pro posed, several discoveries have supported the idea of tumour progenitor genes, including the identification of many of the responsible genes, the role of widespread epigenomic changes involving the nuclear architecture and chromatin compaction, and the parts played by ageing and the environment in these properties.
Nowhere else is the contribution of epigenetic changes to cancer seen more clearly than in paediatric malig nancies. Systematic analyses of genetic and epigenetic alterations in a variety of paediatric cancers have surpris ingly identified tumour types with few or no mutations, suggesting that epigenetic derangements can themselves drive these cancers. The discovery of the biallelic loss of the chromatin remodeller gene SMARCB1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1; also known as SNF5) in highly malignant paediatric rhabdoid tumours was an early example of the disruption of epigenetic control as a driver of cancer 2 . Subsequent exome sequencing of these tumours revealed a remarkably simple genome with no other recurrent genetic mutations 3 . More recently, genome sequencing of paediatric hindbrain ependy momas revealed an absence of any recurrent somatic mutations 4 . The poor prognosis of patients with hind brain ependymomas was instead defined by epigenetic changes, with a CpG island methylator phenotype leading to the transcriptional silencing of Polycomb repressive complex 2 (PRC2) targets. Sequencing efforts in retino blastoma, a childhood cancer that occurs as a result of the inactivation of both copies of the tumour suppressor RB1, found few other genetic alterations 5 . Instead, epi genetic changes predominate, with changes in the gene expression of known oncogenes driven by alterations in histone modifications and DNA methylation. Similarly, the childhood malignant brain tumour medulloblastoma is driven by key subtypespecific somatic mutations, but has a very low mutation rate overall 6 . DNA methyla tion sequencing in medulloblastoma identified highly prevalent epigenetic alterations, most notably consist ing of large regions of hypomethylation correlated with increased gene expression
In this Review, we revisit the tumour progenitor gene model in the light of our much clearer understanding of the identity of these genes, suggesting the more appro priate term 'epigenetic mediator' . We suggest that most driver mutations in cancer occur in 'epigenetic modifi ers' upstream of the mediators, and we integrate the role of upstream 'epigenetic modulators' that sense the envi ronment and regulate stemness epigenetically, largely through the structure of chromatin. We suggest that this framework will be useful in organizing approaches to cancer detection and treatment.
Three types of genes in the epigenetics of cancer There are already two nonepigenetic classification systems for cancer genes: the mutational division into dominant oncogenes and recessive tumour suppressor genes; and the selection division into gene drivers and passengers in tumour development (TABLE 1) . The pro posed epigenetic functional classification system divides cancer genes into epigenetic modifiers, mediators and modulators. The easiest of these to describe are the epi genetic modifiers -that is, the genes whose products modify the epigenome directly through DNA methyla tion, the posttranslational modification of chromatin or the alteration of the structure of chromatin. These genes are frequently the target of mutations and epimutations in cancer. One of the great surprises of the past few years has been the abundance of mutations in cancer involving such genes, affecting almost all levels of the epigenetic machin ery. Also within this group are the genomic sequence changes that affect the binding of chromatin regulators, such as mutations in enhancers or transcription factor binding sites. The epigenetic mediators, which we earlier called tumour progenitor genes, are often the target of epigenetic modification, although they are rarely mutated themselves; importantly, they appear to be responsible for the emergence of cancer stem cells (CSCs). The epigenetic mediators largely overlap with the genes involved in stem cell reprogramming and their role in cancer followed directly from the discovery of their reprogramming role. Epigenetic mediators are those genes whose products are the targets of the epigenetic modifiers. For the most part, these are the genes that drive a tumour or its pro genitor cells towards a more stemlike state. As the ulti mate mediators of the malignant state, they are attractive targets for novel chemotherapy treatments or biological response modifiers. Last, and perhaps most arguable, are the epigenetic modulators, defined as genes lying upstream of the modifiers and mediators in signalling and metabolic pathways, and serving as the mechanism by which environmental agents, injury, inflammation and other forms of stress push tissues towards a neoplastic propensity and/or increase the likelihood that cancer will arise when a key mutation occurs by chance. We suggest that changes in the structure of chromatin are induced very early in the cancer process by epigenetic modulators and even in the nonmutated normal tissues from which tumours arise. Epigenetic modulator genes include many genes with prominent roles in conventional oncogenic signalling; these are increasingly appreciated to influence the epigenome as part of their function (TABLE 1) .
Epigenetic modifiers
A key discovery of largescale cancer sequencing research has been the widespread occurrence of muta tions in epigenetic modifiers (TABLE 2) . These consist of components of nearly every level of the epigenetic machinery, including key players in DNA methylation, histone modification and chromatin organization, across a wide variety of cancer types. This has been the subject of other recent reviews [8] [9] [10] , and we limit our discussion here to a number of illustrative examples.
Mutations in the DNA methylation machinery are common in haematological malignancies. DNA methyl transferase 3α (DNMT3A) is recurrently mutated in myeloid and lymphoid malignancies, especially in acute myeloid leukaemia (AML) and T cell lymphoma [11] [12] [13] . DNMT3A mutation has prognostic value and is associ ated with poorer outcomes in both AML and T cell lymphoblastic leukaemia 14, 15 . Mouse models evaluat ing conditional Dnmt3a knockouts in haematopoietic stem cells (HSCs) revealed enhanced selfrenewal and impaired differentiation of HSCs 16, 17 . It has been shown that transplantation of Dnmt3anull HSCs in mice pre disposes for a spectrum of malignancies similar to that observed in patients with DNMT3A mutations, con firming that DNMT3A loss confers a preleukaemic phenotype in HSCs 18, 19 . Frequent mutations of the methylcytosine dioxy genase enzyme TET2, a DNA methylation eraser, have likewise been observed in myelodysplastic syndrome, myeloid malignancies and T cell lymphoma [20] [21] [22] and is recognized as an unfavourable prognostic factor in AML 23 . Analyses of clonal evolution in myelodysplas tic syndrome and chronic myelomonocytic leukaemia have implicated TET2 mutation as an early oncogenic event [24] [25] [26] . Mouse models of TET2 loss exhibit increased HSC selfrenewal and myeloproliferation in the context of impaired erythroid differentiation, supporting the functional importance of these mutations 20, 27, 28 . Mutations in the chromatin remodelling machinery are widespread in solid tumours. The initial discov ery of the SMARCB1 deletion in paediatric rhabdoid tumours was followed by the identification of patients with germline SMARCB1 mutations and the subsequent loss of the normal allele leading to the development of rhabdoid tumours, confirming a classic tumour suppres sor function for this gene 29 . Cancer sequencing studies have since revealed that genes encoding components of SWI/SNF chromatin remodelling complexes are among the most common targets of mutation. Prominent exam ples (TABLE 2) include polybromo 1 (PBRM1) mutations in over 40% of clear cell renal carcinomas 30 and ATrich interaction domain 1A (ARID1A) mutations in over half of ovarian clear cell carcinomas 31, 32 . The identifi cation of ARID1A mutations in atypical endometriotic lesions adjacent to an ovarian clear cell carcinoma sug gested that ARID1A lossoffunction may occur early in cancer development 32 . Mutations to histonemodifying enzymes are com mon across a diverse range of cancer types. Mutations affecting the SET domain methyltransferase enhancer of zeste homologue 2 (EZH2), a core component of PRC2, appear to have divergent functions in different cancer types. Gainoffunction hotspot mutations and amplifications have been reported in nonHodgkin lymphomas and a variety of solid tumours, suggesting that these tumours depend on increased H3K27 tri methylation (H3K27me3) 33, 34 . This was supported by mouse studies showing that the conditional expression of activated mutant Ezh2 induces germinal centre hyper plasia and accelerates lymphomagenesis 35 . Conversely, lossoffunction mutations of EZH2 are frequently seen in myeloid malignancies, head and neck squamous car cinomas, and T cell leukaemia [36] [37] [38] [39] [40] . Further supporting a transforming influence of EZH2 loss is the finding that EZH2 disruption in mice is sufficient to induce T cell acute lymphoblastic leukaemia 41 . Interestingly, recently described Lys27Met missense mutations in histones H3.3 and H3.1 in the majority of paediatric diffuse intrinsic pontine glioma also serve to inhibit EZH2 enzymatic activity and result in a global decrease in H3K27me3 (REFS 42, 43) . These observations supporting a function for EZH2 as either an oncogene or tumour suppressor in different tissue types highlights the complexity of epigenetic modifier alterations in cancer. Epigenetic modifier mutations are also relevant to cancer progression. Translocations and mutations involving the H3K36 methyltransferases (nuclear recep tor binding SET domain protein 1 (NSD1), NSD2 and SET domain containing 2 (SETD2)) are common across haematological and solid tumours, including paediatric acute lymphoblastic leukaemia, multiple myeloma and renal cell carcinoma [44] [45] [46] [47] . The mechanistic importance of the SETD2 mutation to cancer progression was illus trated by a study examining intratumour heterogeneity in renal cell carcinoma by sequencing spatially sepa rated samples from the same tumour. This revealed that SETD2 underwent multiple distinct inactivating muta tions in different parts of a single tumour, suggesting a selective advantage of this alteration to the progres sion of renal cell carcinoma 48 . Accordingly, the SETD2 mutation is associated with poorer outcomes in renal cell carcinoma 49 . In paediatric acute lymphoblastic leukae mia, comparison of matched patient samples from diag nosis and relapse revealed an enrichment of mutations in epigenetic modifiers, including SETD2, in relapsed disease, supporting a role in cancer progression or resist ance to treatment 50 . Epigenetic modifier mutations in cancer may thus be early events driving carcinogenesis (as in the inactivation of SMARCB1 in paediatric rhab doid tumours or the TET methylcytosine dioxygenase 2 (TET2) mutation in myeloid malignancies), or late muta tional changes related to progression (such as SETD2 in renal cell carcinoma).
Epigenetic mediators
Role of stemness and pluripotency factors. Epigenetic modifiers often target regulatory elements that affect the levels of insulinlike growth factor 2 (IGF2) expres sion and downstream signalling in diverse tumours, such as embryonal tumours of childhood, including Wilms tumour, rhabdomyosarcoma and hepatoblas toma [51] [52] [53] [54] , as well as adult tumours such as colorectal cancer 55 . Loss of imprinting (LOI) of IGF2 is an epigenetic change that modifies the expression of IGF2, leading to a doubling of dosage. LOI of IGF2 was first identified in embryonal tumours of childhood [51] [52] [53] [54] 56 . The dosage of IGF2 is quantitatively related to the growth and number of adenoma 57 and increased levels of IGF2 are linked to both hyperproliferation in nephrogenic rests, which predisposes to Wilms tumour 58 and the increased pro liferation of colon progenitor cells 59 . This information converges on the observations that the IGF2 signalling pathway is a key mediator of the selfrenewal of CSCs in hepatocellular carcinoma 60 . The LOI of IGF2 in the disorder Beckwith-Wiedemann syndrome provided the first causal argument for the role of epigenetic changes in cancer. Beckwith-Wiedemann syndrome is the canonical disorder for a causal epigenetic risk factor in malignancy, similar to tumour protein p53 (TP53) for conventional mutations, because the epi genetic changes in Beckwith-Wiedemann syndrome precede the development of cancer, are associated with premalignant growths (perilobar nephrogenic rests), the epigenetic changes are found in sporadically occurring kidney lesions in newborn infants, and the presence of LOI in Beckwith-Wiedemann syndrome is specifically associated with a substantially increased cancer risk 61 . IGF2 and IGF1 receptor (IGF1R) signalling are thus emerging as key, contextdependent regulators of stem cell selfrenewal and the proliferation of early progeni tor cell pools in normal tissue architectures [62] [63] [64] , tumour tissues 59, 60 and embryonic stem cell (ESC) cultures . The properties of IGF2 in promoting stemness and tipping the balance between the stem/progenitor cell pool and differentiated progeny seems to be tightly connected with its role in cancer initiation and progression 57, 59, 60 . We suggest that factors contributing to a cell state change towards stemcelllike phenotypes have central roles in cancer development and we term these factors epigenetic mediators (FIG. 1; TABLE 1 ). We envisage that epigenetic mediators act at all stages of cancer development by preventing differentiation and eroding barriers against dedifferentiation (FIG. 1) . Epigeneticmediatorinduced alterations in the chromatin landscape of cells of ori gin eventually lead to increased phenotypic flexibility and heterogeneity within the epigenetically altered, precancerous progenitor cell pool; this feature is subse quently selected for and maintained in the tumour tissue during progression. Feinberg et al. 1 hypothesized the existence of a group of tumour progenitor genes that counteract proper maturation programmes when ectopically expressed or overactive. Such genes, we suggest, belong to the epigenetic mediator category and include, for example, wellknown pluripotency factors such as NANOG 66 , OCT4 (also known as POU5F1) 67 and WNT signalling members 68 . Epigenetically altered genes in induced pluri potent stem cells largely overlap epigenetically altered genes in cancer 69 . Experimental evidence in mouse model systems has already established that the ectopic expression of NANOG 66, 70 promotes hyperplastic growth. Furthermore, when challenged with an overactive WNT signalling pathway, the ectopic expression of NANOG in mammary epithelial cells accelerated the development of adenocarcinomas 70 , demonstrating that the unscheduled expression of pluripotency genes can indeed predispose to and drive cancer development. Further highlighting the ability of mediators to reprogramme chromatin states during the initial phase of tumour development, the pre mature termination of in vivo reprogramming towards the pluripotent stem cell state led to cancer development in a mouse model system 71 . Finally, the transient, ectopic expression of OCT4 in vivo induces hyperplastic and dysplastic changes in mouse epithelial tissues and the intestine, with a concomitantly increased progenitor cell pool and increased βcatenin-WNT signalling pathway activity 72 . The persistent, longterm expression of OCT4, on the other hand, results in the histological features of carcinoma in situ and the emergence of invasive tumours in the skin. Hence, although OCT4 is not essential for somatic stem cell maintenance in the mouse model 67 , somatic stem cells retain their ability to respond to pluri potency cues that can lead to impaired cellular differenti ation 72 . As the cancer phenotypes in these mouse models depend on the continuous presence of reprogramming factors instead of the presence of irreversible mutations, mediators probably target the epigenome to bring about changes in cell states on the path to cancer 71, 72 . To destabilize phenotypes and impair differentiation, mediators influence the epigenetic states that define differentiated cell types (FIG. 2) . Cellular differentiation is accompanied by the establishment of large blocks of repressive H3K9me2 and H3K9me3 modifications, which, together with DNA methylation 73 , coordinate the stable, celltypespecific repression of developmen tally regulated genes 74 . These socalled large organized chroma tin K9 modifications (LOCKs) are largely absent from ESCs and cancer cell lines 74 , which may under lie the phenotypic plasticity of these cell states. In line with the role of LOCKs in the maintenance of differenti ated phenotypes, the generation of induced pluripotent stem cells involves the genomewide reprogramming of DNA methylation and histone modifications 75 . Reprogramming of chromatin states are induced in part by the OCT4mediated recruitment of H3K9me2 histone demethylase and chromatin remodelling complexes 76 . Mediatorinduced epigenetic instability and pheno typic plasticity also seem to contribute to tumour evo lution during the later stages of tumour development. The expression of OCT4, for example, plays a key part in human testicular germ cell tumour progression and malignant potential 77 . Similarly, sexdetermining Ybox 2 (SOX2), another core pluripotency factor 78 , is amplified in smallcell lung cancer and squamous cell carcinomas of the lung and oesophagus 79, 80 and is linked to a poor prognosis in a range of human cancers, such as nasopharyngeal carcinoma 81 , lung adenocarcinoma 82 and breast cancer 83 . Finally, NANOG and OCT4 have been associated with increased metastatic potential in breast cancer 70, 83 and lung adenocarcinoma 82 . The underlying mechanism may in all of these cases relate to the fact that OCT4, NANOG and SOX2 form extensive feedforward and feedback loops to organize a stemcell like transcriptional enhancer circuitry in ESCs that not only prevents proper maturation until it is downregu lated 84 , but may also contribute to the heterogeneity of tumour cell states and phenotypes.
Relevance to cancer stem cells. The presence of imma ture cell states with selfrenewal capacity, occupying the socalled CSC states, is well established in tumours [85] [86] [87] . Although such stemcelllike cancer cells make up only a minority of the tumour mass, they have the potential to affect tumour heterogeneity via the stochastic initiation of maturation processes [85] [86] [87] and stochastic transitions between more or less differentiated cellular pheno types 88 . Such phenotypic flexibility of tumour cells is fur ther illustrated by experiments showing that, irrespective of the initial differentiation status, cancer cells are able to reestablish the immature-mature tumour cell mix when cultured individually 89 .
It is important to note that the cell of origin might not be synonymous with CSCs and can be represented by more or less differentiated cell types. For example, mouse model systems have established that the dedif ferentiation of mature intestinal epithelial cells precedes the emergence of cancer cells with stem cell features and tumour formation in the intestine 90 . Furthermore, knocking down tumour suppressor genes in mouse postmitotic neurons led to the generation of glioblas toma stem cells 91 . Examples where the specific targeting of somatic stem cells led to the emergence of CSC states include the observations that activation of the WNT pathway in mouse crypt stem cell populations, but not in transitamplifying progenitor cells, induced the formation of macroadenomas in the mouse intestine 92 . Although the identification of the cell type of origin remains largely elusive in most human cancers, there is good evidence that an initial imbalance between the somatic stem cell and differentiated cell compartments can predispose to cancer, not only in mouse model systems 59 , but also in human tumours 58 . Furthermore, 93 . HSCs also seem to be the cell of origin in more mature lymphoid malignancies, such as chronic lymphocytic leukaemia 94 . In a similar manner to normal stem cells, which occupy specific compartments within tissues, the socalled stem cell niches, cancer cells displaying stem like features frequently thrive in ecological niches in which they strike a symbiotic relationship with the microenvironment to support their propagation and phenotypic plasticity. Thus an overactive IGF2 gene in cancerassociated fibroblasts supports the propagation of lung cancer stem cells 95 , whereas glioblastoma CSCs not only contribute to the endothelial lining, but also gain sustained Notch signalling induced by factors produced by the endothelial lining 96, 97 . Similarly, myofibroblasts produce hepatocyte growth factor to locally support the maintenance of CSC states in the colon and their clonogenicity 98 . Strikingly, factors secreted from myo fibroblasts were also reported to able to induce more dif ferentiated tumour cells to enter into CSC states 98 . Taken together, these examples suggest that cells with stem like features thrive due to their ability to instruct their ectopic microenvironments to render them permissive for the expansion of stemlike cells. There is thus a con stant flux of information within the expanding tumour and between the tumour and its microenvironment on the path to the increased autonomy of tumour cells 87 .
The observations that epigenetic mediators contrib ute not only to the emergence and maintenance of CSC states, but also to tumour progression, indicates that these genes are key players from the very early stages of can cer initiation in cells of origin to metastasis formation (FIG. 2) . If correct, the targeting of epigenetic mediator genes should be central in therapeutic interventions to not only reduce cancer risk, but also to antagonize the growth of the primary tumour and metastatic derivatives (see below).
Epigenetic modulators
Given the central role of epigenetic mediators as repro gramming factors in both development and cancer, the two most important questions are: what underlies their unscheduled activation and how do they reprogramme the epigenome? We suggest introducing the term epi genetic modulators to describe the factors that influence the activity and/or localization of the epigenetic modifiers in order to destabilize differentiationspecific epigenetic states. These epigenetic modulators might also indirectly facilitate the unscheduled expression of epigenetic medi ators and promote the mediatorinduced reprogramming of cellular phenotypes. Epigenetic modulators thus serve to transduce signals from environmental agents, injury, inflammation, ageing and other cellular stressors towards modifiers to alter the chromatin states at tumour suppres sors or oncogenes and to promote epigenetic flexibility and the acquisition of stemlike features early during can cer development. Epigenetic modulator genes are often the targets of driver mutations during the late stages of the disease (FIG. 1; TABLE 1 ).
Oncogenic RAS signalling. Recent reviews have high lighted the importance of chromatin modifications in the spatiotemporal integration of diverse signals from cellular signalling and metabolic pathways 99, 100 . Cancerrelevant signalling pathways thus regulate epigenetic modifiers to indirectly destabilize cellular phenotypes during tumour development (FIG. 1; TABLE 1) . A notable example of epi genetic modulators is oncogenic RAS, which orchestrates global 101 and local [102] [103] [104] chromatin modifications that are Mutations in modulators and modifiers are often selected for during cancer development, which leads not only to increased cell proliferation, but also to the unscheduled expression of mediators that, in turn, inhibit differentiation and promote epigenetic plasticity by affecting the epigenetic modulators and modifiers in a feedback loop. The mechanism of epigenetic instability involves the erosion of barriers against dedifferentiation, such as large organized chromatin K9 modifications (LOCKs) overlapping with lamina-associated domains (LADs), and the emergence of hypomethylated blocks that contain the most variably expressed domains of the tumour genome and interfere with normal differentiation. Increased transcriptional noise at developmentally regulated genes is paralleled by the redistribution of super-enhancers from cell-fate-determining genes to oncogenes that further stabilize the cancer cell state. Stochastic changes in unstable chromatin states lead to the continuous regeneration of epigenetic heterogeneity that manifests as increased cellular entropy and provides the basis for the selection of the fittest during cancer evolution. BRD4, bromodomain containing 4; KLF4, Kruppel-like factor 4. 101 . KRASmediated silencing of a defined set of tumour suppressor genes, on the other hand, is achieved and maintained by sequencespecific transcriptional repressors that target epigenetic modifiers to regulatory elements [102] [103] [104] . Activated KRAS has thus been shown to increase the level of the ZNF304 transcription factor that binds to the SETDB1-KAP1-DNMT1 repressor complex and targets it to the promoter of tumour sup pressor genes located, for example, in the INK4A-ARF (also known as (CDKN2A) locus 104 . Interestingly, silen cing of the same tumour suppressor locus promotes the maintenance of pluripotency in ESCs 104 and serves as the ratelimiting factor for the generation of induced pluri potent stem cells 105 . In line with the profound effects of oncogenic KRAS on the epi genome, lentiviral delivery of mutant KRAS into human basal cells and luminal pro genitors isolated from mammary tissue induced their rapid and efficient transformation accompanied by a loss of lineage specific gene expression. The transformed cells formed and maintained phenotypically heterogeneous, serially transplantable tumours in mice 106 , indicating the successful establishment of selfrenewing CSC states.
Signalling pathways in chronic inflammation. Another prominent example of cancerpromoting pathways regu lating the epigenome is represented by nuclear factorκB (NFκB) signalling, which, in part, mediates the effect of chronic inflammation on cancer predisposition [107] [108] [109] .
Mouse models of intestinal tumorigenesis uncovered that, in the presence of an overactive WNT signalling pathway, NFκB induced the dedifferentiation of mature cells, and promoted the acquisition of stemlike charac teristics and cancer initiation 90 . Furthermore, the aberrant activation of NFκB signalling in the mammary epithe lium in doxycycline inducible mouse models induced altered tissue architecture reminiscent of carcinoma in situ 109 . On the transient activation of the Src oncogene in vitro, NFκB participated in a positive feedback loop with the inflammatory cytokine interleukin6 and tran scription factor STAT3, which mediated a stable pheno typic switch from the immortalized mammary epithelial cell state towards a stably transformed, self renewing state 110 . Intriguingly, STAT3 (REF. 111 ) is a key factor in the maintenance of OCT4, NANOG and SOX2 expres sion by binding to their enhancers during early mouse development 112 . As STAT3 also promotes proliferation, survival 113 and the acquisition of stem cell features in can cer 114 , one possibility is that chronic inflammation leads to unscheduled activation of epigenetic mediator genes in the cells of origin via STAT3 activation (FIG. 1; TABLE 1 ). Although STAT3 can interact with epigenetic modifiers, such as the p300 histone acetlytransferase (HAT), SIN3A histone deacetylase (HDAC) complexes or DNMT1 to influence gene expression, celltype specific transcrip tional effects will probably be influenced by preexisting chromatin marks 115 . Signalling pathways activated by chronic inflammation, such as NFκB signalling, prob ably directly or indirectly modulate several layers of the epigenome [116] [117] [118] , thereby modulating the effects of STAT3 activation. Using a colitisinduced mouse colon cancer model, single base methylation analyses have revealed This hypothetical scheme explains how epigenetic mediators (for example, OCT4) might reprogramme the epigenome to tip over normal somatic stem cells or differentiated progenitor cells into cancer stem cell states displaying phenotypic heterogeneity. Large organized chromatin K9 modifications (LOCKs) (red cloud) overlapping with lamina-associated domains (LADs) are hypothesized to be largely absent in somatic stem cells (left panel) to ensure epigenetic flexibility associated with the multipotent state. The coordination of cell-type-specific repressed states (right panel) within the LOCKs/LADs is facilitated by epigenetic modifiers establishing multiple layers of epigenetic modifications, such as H3K9me2, H3K9me3, and DNA methylation. The localization of LOCKs/LADs to the lamina leads to the separation of active and inactive domains to reduce transcriptional noise and to provide barriers for dedifferentiation. Conversely, the unscheduled activation of epigenetic mediators leads to the erosion of LADs/LOCKs and the emergence of hypomethylated blocks during the neoplastic process. This, in turn, induces phenotypic heterogeneity by increasing the variability in expression and the probability of switches between the diverse cellular states within the tumour. A loss of LOCKs is postulated, moreover, to interfere with the constraints of enhancer-promoter communication within and between topologically associated domains (TADs), enabling the clustering of oncogenic super-enhancers and expression domains (green circles) to coordinate the expression of oncogenic pathway members (centre panel).
that chronic inflammation induces the hypermethylation of several genes important in gastrointestinal homeo stasis and repair, a subset of which is also hypermethy lated in mouse intestinal adenomas and human colorectal cancer 116 , further supporting the view that chronic inflammation is a key modulator of epigenetic lesions early during tumour development. Inflammation might contribute to the ectopic expression of epigenetic medi ators in tumourinitiating cells by the activation of YAP1, a core member of the Hippo pathway 119 , which is able to bind p300 (REF. 120) and is a key regulator of intestinal epithelial regeneration in response to inflammation 119 as well as an activator of OCT4 and SOX2 (REF. 121) in CSCs of nonsmallcell lung cancer.
Tumour suppressor genes as epigenetic modulators.
Further examples of epigenetic modulators in can cer include the tumour suppressor protein p53 (FIG. 1;  TABLE 1 ). Gainoffunction p53 mutations in cancer thus endow p53 with the ability to induce genes encoding the histonemodifying enzymes MLL1, MLL2 (mixedlineage leukaemia) and MOZ, resulting in genomewide increases in histone H3K9 acetylation and H3K4 trimethylation 122 . Mutant p53 was likewise recently shown to enact pro moter remodelling via a physical interaction with the SWI/SNF chromatin remodelling complex 123 . Similarly, the adenomatous polyposis coli (APC) tumour suppressor gene has been shown to control intestinal cell differenti ation via the regulation of DNA methylation dynamics, as a loss of APC upregulates a DNA demethylase system and leads to the hypomethylation of key intestinal cell fate genes 124 ( FIG. 1; TABLE 1 ). Finally, mutations in epigenetic modulators might affect DNA and histone methylation by leading to the production of oncometabolites that inhibit αketoglutaratedependent epigenetic modifiers, such as histone lysine demethylases and TET hydroxylases (FIG. 1;  TABLE 1 ). Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 enzymes may, for example, alter the epigenome of tumour cells and block differentiation by causing the accumulation of the D2hydroxyglutarate oncometabi lite 125 . Furthermore, mutations in fumarate hydratase (FH) and succinate dehydrogenase (SDH) might lead to the accumulation of their substrates, fumarate and suc cinate, which serve as competitive inhibitors of histone demethylases and TET enzymes, consequently altering DNA and histone modifications 126 . Similarly to epigenetic modifiers, modulators are thus often targeted by driver mutations in cancer to promote not only cell proliferation, but also epigenetic instability 127 .
Effects of ageing.
Ageing may influence cancer risk via epigenetic change downstream of epigenetic modula tors and mediators. A comparison of newborn infants and centenarians provided a strong suggestion of age related changes in DNA methylation, subsequently borne out in multiple studies controlling for differences in cell type and exposure [128] [129] [130] [131] , also called epigenetic drift 132 . Interestingly, a recent comprehensive evalu ation of ageassociated DNA methylation changes in blood cells identified megabasescale ageassociated hypomethylated blocks that also showed preferential hypomethylation in agematched cancers 131 . Analyses of chromatin modifications in ageing have also identified multiple ageassociated alterations, including the loss of heterochromatin and a redistribution of activating H3K4me3 marks 133, 134 . A role for epigenetic modifiers in ageing has been reinforced by studies showing that the disruption of histonemodifying enzymes affects lifespan in model systems 134 . Prominent examples include lifespan extension in Caenorhabditis elegans by the disruption of the H3K4 trimethylation machinery and lifespan extension in Drosophila melano gaster by the heterozygous mutation of PRC2 components 135, 136 . A further link between ageing and chromatin altera tions comes from cellular models of premature ageing disorders such as Werner syndrome and HutchisonGilford progeria syndrome. In an ESC model of Werner syndrome, the differentiation of ESCs to mesenchymal stem cells recapitulates cellular ageing and is marked by a global loss of H3K9me3 and changes in heterochromatin architecture 137 . Similarly, in Hutchison-Gilford progeria syndrome, skin fibroblasts show the passagedependent loss of heterochromatin compartmentalization related to altered H3K27me3 marks 138 . Epigenetic modulator sig nalling upstream of agerelated chromatin alterations is only beginning to be defined. In C. elegans, the forkhead box O (FOXO) transcription factor DAF16 serves as an effector of an environmentally responsive insulinlike sig nalling pathway and regulates longevity via recruitment of the SWI/SNF chromatin remodelling complex to tar get genes 139 . Similarly, the energy sensor AMPactivated protein kinase mediates longevity induced by dietary restriction in worms and flies, and impinges on chroma tin regulation via the phosphorylation of HDACs and histone H2B 140, 141 . Ageing is characterized by epigenetic change, and a more thorough understanding of the roles of epigenetic modifiers and modulators in this process is likely to inform our understanding of cancer aetiology and risk.
Effects of environmental exposures.
A crucial role for the dietary availability of methyl donors in cancer pre vention has been demonstrated in animal models and human studies. A methyldeficient diet is sufficient to induce liver neoplasms in rats 142, 143 . Notably, the dietary deficiency of methyl donors in these animals produced global and genespecific DNA hypomethylation 144, 145 . Likewise, human studies have shown that a low dietary intake of folate or methionine increases the risk of colon adenomas 146 . Furthermore, in utero exposure to higher folate and similar onecarbon nutrients has been linked to a reduced risk of childhood acute lymphoblastic leu kaemia, brain tumours and neuroblastoma 147 . Excessive alcohol consumption may increase cancer risk in part via folate depletion. Chronic alcohol consumption in rats results in DNA hypomethylation in the colonic epithe lium 148 . In a human cohort study, low folate and a high alcohol intake were linked to the increased methylation of genes implicated in colorectal cancer 149 . Specific carcinogenic exposures have been shown to perturb the DNA methylome 150 . The aerodigestive tract epithelium of heavy smokers without evidence of
Epigenetic stochasticity
Non-deterministic changes to epigenetic marks such as DNA methylation, giving rise to epigenetic variation that underlies cellular plasticity in both normal and pathological states, and that can be localized to specific genomic regions.
cancer displays the aberrant methylation of multiple genes implicated in the pathogenesis of lung cancer 151 . Similarly, the hypermethylation of genes related to can cer progression was demonstrated in both the bronchial epithelium and peripheral lymphocytes of smokers 152 . Occupational exposure to airborne benzene in humans has been linked to the hypomethylation of repetitive elements as well as genespecific hypermethylation, recapitulating changes also found in malignant cells 153 . Infection with Helicobacter pylori, an aetiological agent in gastric adenocarcinoma and lymphoma, results in increased CpG island methylation in the noncancer ous gastric mucosa 154 , which is reversible on the eradi cation of H. pylori infection 155 . Asbestos, a carcinogen that is not inherently mutagenic, has been suggested to influence cancer risk via an epigenetic mechanism. Accordingly, DNA methylation profiles distinguish pleu ral meso theli oma from normal pleura and predict the lung burden of asbestos 156 . Although the link between epigenetic modifiers, environmental exposure and can cer risk is clearly established, much less is known about the identity of signalling pathways and epigenetic modu lators that causally connect carcinogens to the writers of the epigenome.
Deregulated 3D nuclear architecture
Alterations of the epigenome during ageing and in can cer are tightly interconnected with the 3D organization of chromatin 157 that modulates chromatin states in both development and cancer (FIG. 2) . Hypomethylated blocks thus overlap with laminaassociated domains (LADs) 158 , which contain repressed, genepoor regions constitu tively localizing to the nuclear periphery, and develop mentally repressed genes that are recruited to the lamina in a celltypespecific manner 159 . In differentiated cells, a significant fraction of LADs overlaps with large domains enriched in repressive H3K9me2 and H3K9me3 histone modifications called LOCKs 74 , which expand during differentiation to coordinate celltypespecific transcrip tional repression [160] [161] [162] . Interestingly, downregulation of the epigenetic mediator gene OCT4 coincides with the formation of compact chromatin at the lamina in mice 163 , suggesting that 3D chromatin compaction itself might contribute to repression [164] [165] [166] during lineage specification. Repressive chromatin marks and peripheral local ization are functionally intertwined 167 and might be particularly sensitive to ageingrelated and cancer predisposing perturbations [167] [168] [169] (FIG. 2) . The recruit ment of certain genomic regions to the repressive environment of the nuclear envelope is promoted by sequencespecific transcriptional repressors 170 , factors that deposit and recognize repressive histone modi fications (H3K9me2/me3 (REF. 170 ) and H3K27me3 (REFS 170,171)), DNA methylation binding proteins 172 and components of the nuclear envelope 167 . These fac tors thus act as epi genetic modulators by regulating the position of genomic regions within the 3D nucleus. In turn, the lamina modu lates chromatin states by attract ing repressive epigenetic modifiers, such as lysine specific histone demethylase 1A (KDM1A; also known as LSD1) 173 , histonelysine Nmethyltransferase EHMT2 (also known as G9A) 174 , HDAC3 (REFS 175, 176) and the nuclear corepressor (NCoR) complex 177 that maintain a repressive environment at the nuclear periphery 167, 178 . These epigenetic modifiers balance selfrenewal and dif ferentiation 179, 180 , affect reprogramming into the pluri potent state 181 and contribute to ageingrelated chromatin changes 182, 183 and cancer 183, 184 , suggesting that their mech anism of action ties spatiotemporal compartmentaliza tion in the nucleus to the modulation of the epigenome and cellular states (FIG. 2) .
In agreement with the role of LOCKs in the main tenance of cellular memories, tumour growth factorβ (TGFβ)induced epithelialtomesenchymal transi tion (EMT) is preceded by the dualspecific lysine demethy lase, LSD1mediated global loss of H3K9me2 at LOCKs 185 . Chromatin changes in EMT are reminiscent of ESCs with reduced LOCKs, although the epigenetic modulators that direct LSD1 activity from H3K4me2 demethylation towards H3K9me2 demethylation within LOCKs on treatment with TGFβ and the role of this epi genetic modifier in regulating the levels of H3K9me2 and H3K9me3 in pluripotent cells have not yet been identified 74, 185, 186 . Importantly, these experiments might provide mechanistic support for the earlier observations that link EMT phenotypes to the acquisition of stem cell traits 74, 185, 186 . Cancer cells might thus gain phenotypic plasticity by acquiring EMTrelated chromatin changes leading to the impaired stabilization of cellular memo ries (FIG. 2) . Hence regions displaying a loss of H3K9me2 and H3K9me3 in various cancer cell lines overlap with hypomethylated blocks and the location of increased variability in the gene expression of cancerrelevant and developmentally regulated genes in diverse cancer types 157 . We envisage that developmental decisions are stabilized by multiple layers of epigenetic modifications, which are established and/or maintained at the lamina. The factors that regulate chromatin-lamina inter actions and recruit chromatinmodifying enzymes to the nuclear periphery might thus act as epigenetic modu lators by positioning the genome within the nucleus and coordinating the activity of epigenetic modifiers in space and time (FIG. 2) . A failure to orchestrate such spatio temporal crosstalk between repressive chromatin factors will probably lead to the emergence of cells with unstable phenotypes of impaired differentiation. Some of these cells might maintain or regain selfrenewal capacity due to epigenetic mediator gene products, representing transition cell fates towards CSCs (FIG. 3) .
Epigenetic stochasticity Large domains of epigenetic variability. We have previ ously suggested that a major driving force for tumour evo lution is the emergence of epigenetic stochasticity, allowing rapid selection for growthfavouring tumour traits in a changing microenvironment [187] [188] [189] . Understanding the nature and genomic location of such stochastic vari ation, as well as the interplay between epigenetic modi fiers, epigenetic modulators and epigenetic mediators that destabilize the epigenome to increase stochastic noise, is thus likely to be essential in tackling tumour evolution and resistance to treatment. Experimental evidence has confirmed that stochastic DNA methy lation alterations in cancer involve large regions of the epigenome 190, 191 . This stochastic epigenetic change does not occur genomewide. Rather, genomewide views of epigenetic variation have shown that large hypomethy lated blocks, constituting up to onethird of the genome, contain the most variably methylated regions of the tumour genome 190, 192 . These domains arise early during cancer development 191, 193, 194 and contain the most variably expressed genes regulating cancer relevant functions 190 . Moreover, the degree of variation in methylation in early precursor lesions predicts cancer risk 193, 194 , suggesting a causal link between these epigenetic changes and cancer. Hypomethylated blocks in cancer largely correspond to partially methylated domains in normal cells as well as LADs and LOCKs (FIG. 2) . These regions underlie much of the reported variation in methylation at CpG islands, shores and distant CpG sites, fuelling phenotypic vari ation in cancer 191, 192 . In addition, the degree of vari ation in methylation 191 , as well as the deviation of the vari ability in gene expression from the normal correspond ing tissue, is a predictor of cancer progression 195 . The combination of ageing and chronic sun exposure -the two leading causes of skin cancer -induces the wide spread formation of hypomethylated blocks in the epi dermis at genomic regions that are hypomethylated in squamous cell carcinoma and that overlap with colon cancer specific hypomethy lated blocks 196 . These same regions are the very ones that show further alterations in methylation in squamous cell cancers arising within the same skin. Given the overlap of these regions with LADs and LOCKs, these data also indicate that the inter play between altered 3D genome organization, stochastic epigenetic change and impaired differentiation mediate the effect of environmental damage with photoageing 196 . Network entropy and nuclear structure. Recent work has described cellular heterogeneity as network entropyapplied as a measure of signalling pathway promiscuity -and established that the level of network entropy provides an estimate of developmental potential 160, 197 . In other words, the high entropy of a heterogeneous pluri potent stem cell population maintains a diverse range of pathways associated with more mature pheno types in a poised state for activation. Consistent with the signalling entropy model of cellular differentiation, the variability in the expression of signalling factors and developmen tal regulators has been experimentally linked to the dif ferentiation potential of ESCs 198 . In a similar manner to normal differentiation, CSCs display a higher entropy than cancer cells, although the difference is smaller than between normal stem cells and differentiated progeny 160 . Furthermore, CSCs consistently have a lower entropy than their normal counterparts, indicating the presence of dominating oncogenic pathways. This is in agreement with models suggesting that cancers represent hybrid states between aberrantly increased as well as decreased epigenetic flexibility 188 (FIG. 3a) .
Importantly, transitions between cellular states of different entropy seem to be regulated epigeneti cally. Using quantitative RNA fluorescence in situ Cancer stem cell (CSC) states (yellow ball) arise when epigenetic instability interferes with normal differentiation and leads to the erosion of barriers against dedifferentiation -for example, via the erosion of large organized chromatin K9 modifications and the emergence of hypomethylated blocks. In a similar manner to normal differentiation, CSCs with higher entropy occupy higher altitudes on the hill than cancer cells (orange and red balls), although the difference is smaller than between normal stem cells and differentiated progeny. Increased transcriptional noise (shallow valleys) and stochastic switches between diverse cell states (arrows between valleys) are regulated by the interplay between epigenetic modulators, modifiers and mediators, the deregulated epigenome and fluctuating environmental cues (for example, inflammation, repeated exposure to carcinogens, ageing or an overactive WNT pathway). Finally, cellular heterogeneity (yellow, orange and red balls) within the tumour eventually enables selection mechanisms to drive the growth of the fittest clone. b | Illustration of the role of epigenetic modifiers, modulators and mediators on the Waddington landscape described in part a. Epigenetic modulators (pink hexagon) regulate the activity of epigenetic modifiers (green triangles) that induce the ectopic expression of epigenetic mediators. Mediators dynamically alter the contour of the landscape via feedback loops that target epigenetic modifiers such as chromatin modifications (blue circles), lamin proteins (yellow circles) and chromosomal interactions (new loop on right). The expression of epigenetic mediators thus produces a shift in the epigenetic landscape, enabling the sampling of aberrant developmental outcomes displaying increased phenotypic plasticity in neoplastic or pre-neoplastic cells. APC, adenomatous polyposis coli; DNMT, DNA methyltransferase; SOX2, sex-determining Y-box 2; STAT3, signal transducer and activator of transcription 3; TET, TET methylcytosine dioxygenase.
Canalization
The ability of an organism to produce a consistent developmental outcome despite variations in its environment.
hybridization in combination with timelapse movies, the transient stabilization of distinct, noisy expression patterns that predict the potential for differentiation has been linked to changes in the global level of DNA methylation in ESCs 199 . These findings highlight that changes in DNA methylation might stabilize not only irreversible, but also reversible cell fate transitions, and regulate stochastic switches between states. As opposed to the short timescales of transcription bursts, the long timescales of infrequent state switching follow a stochas tic bistable switch model regulated by methylation and demethylation. Interestingly, ESCs and testicular cells display a bimodal and coherent methylation pattern that becomes variable during differentiation and with age 200 . Further supporting the model in which stochastic variation in fuels aberrantly increased cellular hetero geneity, Epstein-Barr virus immortalization of human B cell cultures induces the emergence of hypomethylated blocks linked with hypervariable DNA methylation and gene expression 158 . In summary, these experiments are consistent with a model in which inherently stochastic DNA methylation variation unleashed within hypo methylated blocks continuously reestablishes tumour cell heterogeneity and thereby promotes the adaptation of the tumour tissue to changing microenvironments, facilitating the survival and growth of tumour cells outside the context of normal tissue architecture and at metastatic sites 188 (FIG. 3a,b) .
Mechanism of stochastic epigenetic variation.
Recent experiments suggest that the molecular mechanisms of increased stochastic epigenetic variation might involve deregulated spatial separation between active and inactive chromatin environments and/or altered chro matin mobility between different subcompartments of the nucleus 74, 157, 188, 201, 202 . In accordance with the revers ible nature of chromatin modifications, the relocation of LADs and LOCKs away from the lamina has thus been linked to the erosion of repressive marks and an increase in transcriptional activity 203 . Importantly, the longterm stability of H3K9me2 marks in cycling cells seems to be ensured via the stochastic reestablishment of chromatin-lamina interactions in the G1 phase of the cell cycle 203 . Compromised recruitment of inactive chro matin domains to the lamina in G1 might thus lead to the heterogeneous erosion of LOCKs within a cell popu lation, leading to stochastic reactivation of genes located within these domains. Similarly, the stochastic reloca tion of genes to the periphery might contribute to vari egated silencing -that is, celltocell variation in gene transcription depending on the subnuclear position, a phenomenon that also includes stochastic allelic exclu sion that limits the production of antigen receptors to a single allele per cell 204 . Moreover, circadian chromatin transitions are also linked to the transient recruitment of clockcontrolled loci to lamina 205 . 3D genome organiza tion itself thus emerges as an epigenetic modulator that fine tunes the spatiotemporal aspects of epigenetic modi fier activities to affect phenotypic plasticity in develop ment and cancer (FIG. 3b) . We hypothesize that epigenetic mediators promote the emergence of cancer stemlike states and phenotypic flexibility in part by counteracting the formation of repressive subnuclear compartments and the spatial separation between active and inactive chromatin domains. This is likely to require crosstalk between the epigenetic mediators and epigenetic modu lators that regulate the dynamics of the 3D nuclear archi tecture, as well as interaction with epigenetic modifiers to disrupt the multiple layers of epigenetic modifications that establish the differentiated cell state. Very little is known about how different epigenetic perturbations in cancer synergize to deregulate 3D genome organization and influence transcriptional variability. Nonetheless, an interesting opening is provided by the findings that impaired PRC2 function leads to a stochastic loss of repression and increased transcriptional variability at PRC2 target genes, which is linked to a poor progno sis 206 . H3K27me3 modifications are moreover enriched in LADs close to LAD boundaries 207 and have not only been linked to the recruitment of genomic regions to the lamina 170 , but are also suggested to collaborate with H3K9me3 marks to promote HP1 binding to chroma tin 208 , with potential consequences on the stringency of transcriptional repression genomewide.
Enhancer usage
Enhancer elements integrate signals from develop mental and oncogenic pathways, as well as chromatin organization, to modulate the probability and variabil ity of transcriptional bursts at the associated transcrip tional units 79, [209] [210] [211] . We envisage that tumourspecific 3D chroma tin organization modulates the epigenome and undermines differentiation in part by affecting the specificity and dynamics of enhancer-promoter com munication. Global maps of chromatin contacts have thus uncovered longrange enhancer-promoter loops within and between chromosomes 212 that fine tune the celltocell variability of gene expression, potentially providing selectable features in a cell population 213 . Conversely, the robustness of celltypespecific gene expression is ensured by the local clustering of multiple enhancer elements in cis spanning tens or hundreds of kilobases 214 . These socalled super enhancers evolved to integrate signals from multiple cellfatedetermining pathways to ensure a high probability of transcription at genes defining cellular states 209 . Factors regulating epigenetic modifiers that establish enhan cerspecific chromatin states and molecular ties regulating enhancerpromoter interactions might therefore act as epigenetic modulators that influence not only the mean level of transcription, but also its variance 213 , thereby affecting phenotypic variation (FIG. 3b) .
Tumour cells often establish de novo oncogenic superenhancers that drive proliferation 209, 215 and are hypersensitive to fluctuations in the level of bromo domain containing 4 (BRD4) and the Mediator complex -an essential cofactor regulating enhancer-promoter contact 216 . Importantly, the location and activity of superenhancers is stabilized by the cellular micro environ ment of the stem cell niche 217 , uncovering the sur prising sensitivity of superenhancer formation in stem/ progenitor cells to environmental perturbations (FIG. 2) .
Pleiotropic
Genetic or epigenetic changes that affect multiple seemingly unrelated phenotypic traits.
Non-linear dynamics
The behaviour of a system in which a small change in an input variable can induce a large change in the output. Modelling of chromatin structure and of the impact of chromatin states on transcription has demonstrated non-linear behaviour.
Waddington landscape
A metaphor of development, in which valleys and ridges illustrate the epigenetic landscape that guides a pluripotent cell to a well-defined differentiated state, represented by a ball rolling down the landscape.
Enhancer-promoter crosstalk is further constrained by the organization of the genome into topologically associated domains (TADs), which we suggest are cat egorized as epigenetic modulators based on their role in constituting an additional layer of regulation in set ting up gene expression domains 218 . Importantly, the boundary strength of TADs is linked to the presence of architectural proteins, such as CCCTCbinding factor (CTCF) 218, 219 , an epigenetic modulator (TABLE 1) that binds to DNA in a methylationsensitive manner 220 . Reprogramming of such boundaries by widespread DNA methylation alterations present in tumours might further contribute to the loss of celltypespecific expres sion domains and might alter the mobility and reach of oncogenic superenhancers. Developmentally regulated contacts between chromatin fibres thus provide a 3D framework for celltypespecific enhancer usage that might be reprogrammed in tumours to drive variation in stochastic gene expression and diversify the array of tumourspecific cellular states to enable tumour evolu tion (FIGS 2,3b). Although the mechanism by which epi genetic mediators, such as OCT4, NANOG and SOX2 (TABLE 1) promote the emergence of stemlike cell states in cancer cells is not fully explored, it is likely to involve the efficient reprogramming of 3D enhancer-promoter crosstalk that maintains differentiated cell states.
Relevance to diagnosis and treatment Epigenetic chemoprevention to revert or prevent can cerpredisposing polyclonal epigenomic alterations in the progenitor cell compartments might be achieved by inhibiting epigenetic mediators, such as IGF2 signalling. Primary epigenetic changes are thus likely targets for early intervention to prevent tumour progression.
It will be important to consider that mutations in epi genetic modulators and modifiers can arise early in can cer, but a comparatively long time after the poly clonal epigenetic disruption of normal tissue affected by age and the environment through epigenetic modu lators. For example, in renal cell carcinoma multiple distinct mutations in different parts of a single tumour converge on the same histone methylation change, suggesting that these mutations arise during progression rather than initi ation 48, 221 . These observations thus pinpoint epi genetic modifiers as therapeutic targets of exist ing tumours to prevent progression. The model also highlights the importance of overlooked approaches to epigenetic drug design and warrants new ways of thinking about assays for drugs rather than half max imal inhibitory concentration (IC 50 ). This is exempli fied by pleiotropic, epigenomewide changes caused by gainoffunction mutations in variant histones, such as H3.3 and H3.1 in paediatric gliomas 42, 43 . The nonlinear dynamics of chromatin 222, 223 thus make the drug dose crucial when attacking epigenetic modifiers. An example is recent work profiling the effects of anthra cycline drugs on histone eviction from chromatin 224 . The authors found that aclarubicin evicts histones from H3K27me3marked hetero chroma tin and shows selec tive toxicity to diffuse large B cell lymphoma cells with increased levels of H3K27me3.
The prominent role of epigenetic instability in the emergence of cancer stem cells and tumour evolution provides an opportunity to reverse drug resistance and deplete CSCs by inhibiting epigenetic mediators. One remarkable opening for such a strategy is offered by the demonstration that tryptophan derivatives regu late OCT4 transcription in stemlike cancer cells 225 . One of these compounds, 2(1ʹHindole3ʹcarbonyl) thiazole4carboxylic acid methyl ester (ITE), enhanced the binding of the aryl hydrocarbon receptor to the pro moter of OCT4 to suppress its transcription. Accordingly, administration of synthetic ITE reduced the tumorigenic potential of stemlike cells in both subcutaneous and xenograft tumour models 225 .
Conclusions and future perspectives
The past decade has provided exciting new evidence demonstrating that cancer epigenomes display consid erable instability, which leads to the continuous regener ation of epigenetic variation under the selection pressure of the tumour microenvironment 190, 191 . One of the most surprising findings of these experiments is that certain domains of the genome seem to be particularly vulner able to ageing and environmentalcarcinogeninduced epigenetic alterations, which can then unleash stochas tic epigenetic changes within such vulnerable domains early during cancer development 190, 191 . Ten years ago Feinberg et al. 1 argued that environmental signals and ageing could affect epigenetic modifiers and lead to the emergence of an epigenetically disrupted progenitor cell pool long before the emergence of oncogenic mutations on the path to cancer. Such epigenetic variation would then drive phenotypic variation during cancer progres sion and evolution 1 . Since then, experimental evidence has already accumulated to confirm this prediction, warranting the accurate assessment of the level of tran scriptional variation and the contribution of determin istic versus stochastic variation within the epigenome to cancer development. Such an endeavour is likely to require the development of singlecell techniques capable of quantitatively measuring a diverse array of epigenetic modifications at high resolution.
To provide a conceptual framework for the functional characterization of the genes that rewire the epigenome during cancer development and progression (FIG. 1;  TABLE 1 ), we have introduced here a novel classification system that differentiates between epigenetic modifiers and the epigenetic modulators that regulate modifiers, and epigenetic mediators that shape the Waddington landscape of development to shift the phenotype towards stemlike states displaying phenotypic plasticity (FIG. 3) . Epigenetic modifiers and epigenetic modulators (TABLE 1) are often mutated in cancer, or transmit signals from oncogenic sig nalling pathways that indirectly alter local or global chro matin modifications to promote tumour development. We suggest that chromatin states at epigenetic mediator genes are vulnerable targets for cancer predisposing envi ronmental cues that destabilize the epigenome via signal ling and metabolic pathways that impinge on epigenetic modulators. As epigenetic mediators influence pheno typic plasticity during the entire neoplastic process, from the formation of CSC states to malignant derivatives and metastases, these factors should constitute prime targets for both prevention and therapeutic interventions.
The mechanism of increased epigenetic variation in cancer appears to be functionally connected to the per turbations of the 3D organization of the genome and the architecture of the nucleus (FIGS 2,3) . Factors that regu late the nuclear architecture and enhancer-promoter communication might thus modulate the epigenome by coordinating the spatiotemporal aspects of epigenetic modifier activity. Moreover, the 3D genome organization in itself seems to affect the epigenome and function as an epigenetic modulator. The physical separation between active and inactive chromatin environments and the for mation of TADs constraining enhancer-promoter con tacts are thus likely to modulate the level of stochastic variation in epigenetic marks (FIG. 3b) . Measuring the impact of deregulated nuclear compartmentalization on phenotypic traits that are selected for on the path to can cer requires the invention of sensitive and quantitative methods that can translate celltocell variations of 3D chromatin organization to transcriptional heterogeneity in small cell populations representing transition cell fates towards CSCs.
We emphasize that the findings of the past 10 years also call for the integration of normal tissue epigenom ics into precision medicine funding to promote progress in largely unexplored research areas in the context of cancer progenitors, such as RNA, tumour heterogeneity, transcriptional stochasticity, the contribution of inflam mation and cell signalling, and enhancer-promoter interactions, to name but a few.
